EUCTR2017-000236-34-PT进行中（未招募）1 期
Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial - ELA
Inselspital (University Hospital) Bern0 个研究点目标入组 2,013 人开始时间: 2020年8月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,013
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent
- •Age: =18 years
- •Acute ischaemic stroke, either confirmed by MRI or CT scan (tissue based definition) or by sudden focal neurological deficit of presumed ischaemic origin that persisted beyond 24 hours and otherwise normal non-contrast CT scan. Please note: prior intravenous or endovascular treatment is allowed.
- •Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed during the index hospitalization
- •Agreement of treating physician to prescribe DOACs
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1500
排除标准
- •Atrial fibrillation due to reversible causes (e.g. thyrotoxicosis, pericarditis, recent surgery, myocardial infarct)
- •Valvular disease requiring surgery
- •Mechanical heart valve(s)
- •Moderate or severe mitral stenosis. Please note that other valvular diseases and biological valves are eligible
- •AF and conditions other than AF that require anticoagulation, including therapeutical dose of low-molecular-weight heparin or heparin. Please note: infratherapeutic anticoagulation at ischaemic stroke onset defined as follows is not an exclusion criteria:
- •o Vitamine K antagonist: International Normalized Ratio (INR) < 1.7
- •o Anti-IIa: thrombin time < 80 seconds and/or anti-IIa < 50 ng/ml
- •o Anti-Xa: anti-Xa < 50 ng/ml
- •Subject who is contraindicated to DOACs
- •Female who is pregnant or lactating or has a positive pregnancy test at time of admission
- •Patients with serious bleeding in the last 6 months or at high risk of bleeding (e.g. active peptic ulcer disease, platelet count < 100’000/mm3 or haemoglobin < 10 g/dl or INR = 1.7, documented haemorrhagic tendencies or blood dyscrasias)
- •Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than four alcoholic drinks per day)
- •Severe comorbid condition with life expectancy < 6 months
- •Severe or moderate renal insufficiency as defined by creatinine clearance < 50 ml/min
- •Subject who requires haemodialysis or peritoneal dialysis
- •Subject with aortic dissection
- •Current participation in another investigational trial
- •Dual antiplatelet therapy at baseline or strong likelihood to be treated with dual antiplatelet therapy during the course of the trial
- •CT or MRI evidence of haemorrhage classified as PH1 (defined as parenchymal haemorrhage = blood clots in < 30% of the infarcted area without or with slight space-occupying effect) and PH2 (defined as blood clots in > 30% of the infarcted area with a substantial space-occupying effect) independently of clinical deterioration. Please note that HI1 (defined as haemorrhagic infarct = small petechiae along the margins of the infarct) and HI2 (defined as confluent petechiae within the infarcted area but no space occupying effect) are acceptable if not associated with clinical deterioration and if the treating physician feels comfortable to treat patients with DOACs.
- •CT or MRI evidence of mass effect or intra-cranial tumour (except small meningioma)
- •CT or MRI evidence of cerebral vasculitis
- •Endocarditis
- •Evidence of severe cerebral amyloid angiopathy if MRI scan performed
研究者
相似试验
进行中（未招募）
1 期
Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm,assessor-blinded trialRecurrent strokes in patients with atrial fibrillation who suffered from an ischaemic strokeMedDRA version: 22.0Level: LLTClassification code 10082513Term: Recurrent strokeSystem Organ Class: 100000004852EUCTR2017-000236-34-SKInselspital (University Hospital) Bern2,000
招募中
不适用
Earlier treatment start of direct oral anticoagulants after a stroke due to atrial fibrillation, compared to current clinical practice (later start)CTRI/2021/01/030322Inselspital University Hospital Bern
进行中（未招募）
1 期
Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm,assessor-blinded trialRecurrent strokes in patients with atrial fibrillation who suffered from an ischaemic strokeEUCTR2017-000236-34-DEInselspital (University Hospital) Bern2,000
进行中（未招募）
1 期
Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trialRecurrent strokes in patients with atrial fibrillation who suffered an ischaemic strokeMedDRA version: 20.0Level: LLTClassification code 10001434Term: AFSystem Organ Class: 100000004849MedDRA version: 22.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-000236-34-ITInsel Gruppe AG, Bern University Hospital, Department of Neurology2,000
进行中（未招募）
1 期
Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trialRecurrent strokes in patients with atrial fibrillation who suffered an ischaemic strokeEUCTR2017-000236-34-FIInselspital (University Hospital) Bern2,000